Molecular Imaging for Estrogen Receptor-Positive Breast Cancer

Breast cancer facts and statistics.

() ()Carlson R.W. Hudis C.A. Pritchard K.I.

National comprehensive cancer network breast cancer clinical practice guidelines in oncology, american society of clinical oncology technology assessment on the use of aromatase inhibitors, St Gallen international expert consensus on the primary therapy of early breast cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

J Natl Compr Cancer Netw. 4: 971-979Brown-Glaberman U. Dayao Z. Royce M.

HER2-targeted therapy for early-stage breast cancer: a comprehensive review.

Oncol Williston Park N. 28: 281-289Li H. Liu Z. Yuan L. et al.

Radionuclide-based imaging of breast cancer: state of the art.

Cancers. 13: 5459

Novel methods and tracers for breast cancer imaging.

Semin Nucl Med. 43: 324-329McElvany K.D. Katzenellenbogen J.A. Shafer K.E. et al.

16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies.

J Nucl Med. 23: 425-430Mintun M.A. Welch M.J. Siegel B.A. et al.

Breast cancer: PET imaging of estrogen receptors.

Radiology. 169: 45-48Boers J. de Vries E.F.J. Glaudemans A.W.J.M. et al.

Application of PET tracers in molecular imaging for breast cancer.

Curr Oncol Rep. 22: 85

Breast cancer: evaluating tumor estrogen receptor status with molecular imaging to increase response to therapy and improve patient outcomes.

J Nucl Med Technol. 48: 191-201van Kruchten M. de Vries E.G.E. Brown M. et al.

PET imaging of oestrogen receptors in patients with breast cancer.

Lancet Oncol. 14: e465-e475Yoo J. Dence C.S. Sharp T.L. et al.

Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol.

J Med Chem. 48: 6366-6378Chae S.Y. Ahn S.H. Kim S.B. et al.

Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.

Lancet Oncol. 20: 546-555Chae S.Y. Kim S.B. Ahn S.H. et al.

A randomized feasibility study of 18F-Fluoroestradiol PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer.

J Nucl Med. 58: 563-568Gemignani M.L. Patil S. Seshan V.E. et al.

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.

J Nucl Med. 54: 1697-1702

FDA label cerianna.

() ()Mankoff D.A. Peterson L.M. Tewson T.J. et al.

[18F]Fluoroestradiol radiation dosimetry in human PET studies.

J Nucl Med. 42: 679

PET oestrogen receptor imaging: ready for the clinic?.

Lancet Oncol. 20: 467-469Linden H.M. Kurland B.F. Peterson L.M. et al.

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Clin Cancer Res. 17: 4799-4805Evangelista L. Dieci M.V. Guarneri V. Conte P.F.

18F-Fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis..

Curr Radiopharm. 9: 244-257Kurland B.F. Wiggins J.R. Coche A. et al.

Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16α-18F-Fluoro-17β-Estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications.

Oncologist. 25: 835-844Ivanidze J. Subramanian K. Youn T. et al.

Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer.

Neurooncol Adv. 3: vdab178

The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Nucl Med Biol. 92: 24-37Mortimer J.E. Dehdashti F. Siegel B.A. et al.

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

J Clin Oncol. 19: 2797-2803Linden H.M. Stekhova S.A. Link J.M. et al.

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

J Clin Oncol. 24: 2793-2799Dehdashti F. Mortimer J.E. Trinkaus K. et al.

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.

Breast Cancer Res Treat. 113: 509-517Kurland B.F. Peterson L.M. Lee J.H. et al.

Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.

Clin Cancer Res. 23: 407-415van Kruchten M. de Vries E.G. Glaudemans A.W. et al.

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

Cancer Discov. 5: 72-81Johnston S.R.D. Harbeck N. Hegg R. et al.

Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE).

J Clin Oncol. https://doi.org/10.1200/JCO.20.02514Boers J. Venema C.M. de Vries E.F.J. et al.

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.

Eur J Cancer Oxf Engl 1990. 126: 11-20Peterson L.M. Kurland B.F. Yan F. et al.

18F-Fluoroestradiol PET imaging in a phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.

J Nucl Med. 62: 184-190Wang Y. Ayres K.L. Goldman D.A. et al.

18F-Fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials.

Clin Cancer Res. 23: 3053-3060van Kruchten M. Glaudemans A.W.J.M. de Vries E.F.J. et al.

PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.

J Nucl Med. 53: 182-190Sun Y. Yang Z. Zhang Y. et al.

The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.

PLoS One. 10: e0116341Venema C. de Vries E. Glaudemans A. et al.

18F-FES PET has added value in staging and therapy decision making in patients with disseminated lobular breast cancer.

Clin Nucl Med. 42: 612-614Ulaner G.A. Jhaveri K. Chandarlapaty S. et al.

Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer.

J Nucl Med. 62: 326-331Boers J. Loudini N. de Haas R.J. et al.

Analyzing the estrogen receptor status of liver metastases with [18F]-FES-PET in patients with breast cancer.

Diagn Basel Switz. 11 ()Koleva-Kolarova R.G. Greuter M.J.W. Feenstra T.L. et al.

Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.

Oncotarget. 9: 19836-19846Peterson L.M. Kurland B.F. Link J.M. et al.

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Nucl Med Biol. 38: 969-978Hathi D.K. Li W. Seo Y. et al.

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.

Sci Rep. 10: 21930Jones E.F. Ray K.M. Li W. et al.

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

NPJ Breast Cancer. 5: 1-6Miyake K.K. Kataoka M. Ishimori T. et al.

A proposed dedicated breast pet lexicon: standardization of description and reporting of radiotracer uptake in the breast.

Diagn Basel Switz. 11: 1267Liao G.J. Clark A.S. Schubert E.K. et al.

18F-Fluoroestradiol PET: current status and potential future clinical applications.

J Nucl Med. 57: 1269-1275van Kruchten M. Glaudemans A.W.J.M. de Vries E.F.J. et al.

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

Eur J Nucl Med Mol Imaging. 42: 1674-1681

18F-Fluoroestradiol (FES) PET/CT Compared to standard-of-care imaging in patients with breast cancer. clinicaltrials.gov.

() ()

Gennari A, Brain E, Nanni O, et al. 114P - Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): a European TRANSCAN program. Annals of Oncology 2017;28(suppl_5): v22-v42. doi:10.1093/annonc/mdx363.030

留言 (0)

沒有登入
gif